News articles about Sunesis Pharmaceuticals (NASDAQ:SNSS) have been trending somewhat positive this week, according to Accern Sentiment. The research firm identifies positive and negative media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Sunesis Pharmaceuticals earned a news impact score of 0.19 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.1348239165863 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of Sunesis Pharmaceuticals (SNSS) traded down 2.04% during trading on Monday, reaching $1.92. 37,622 shares of the company’s stock were exchanged. The stock has a 50-day moving average price of $2.26 and a 200 day moving average price of $3.05. Sunesis Pharmaceuticals has a 12 month low of $1.86 and a 12 month high of $5.00. The firm’s market cap is $45.14 million.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.76) by $0.35. During the same period in the prior year, the company earned ($0.12) EPS. On average, analysts forecast that Sunesis Pharmaceuticals will post ($1.61) EPS for the current year.

Several equities analysts recently weighed in on SNSS shares. ValuEngine lowered shares of Sunesis Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Cantor Fitzgerald reiterated a “hold” rating and set a $3.00 target price on shares of Sunesis Pharmaceuticals in a research report on Thursday, July 27th. Finally, Zacks Investment Research upgraded shares of Sunesis Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, August 2nd.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Sunesis Pharmaceuticals (SNSS) Share Price” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Insider Buying and Selling by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)

Receive News & Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.